Halia Therapeutics, Inc.

United States · Research

Halia Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Lehi, Utah. The company is focused on developing innovative treatments for chronic inflammatory disorders and neurodegenerative diseases. Halia Therapeutics aims to improve patient quality of life by creating novel therapeutics that address the root causes of inflammation-driven diseases. The company is advancing a pipeline of differentiated small molecules, including its lead candidate HT-6184, a first-in-class NEK7/NLRP3 inflammasome inhibitor. This compound is designed to target metaflammation related to obesity and metabolic dysfunction and is also being explored for lower-risk myelodysplastic syndromes. Other candidates in development include HT-4253, a LRRK2 inhibitor, along with several additional compounds targeting various inflammatory and neurodegenerative conditions. Halia Therapeutics has received the Novo Nordisk Golden Ticket, which supports its research efforts and enhances its position in the biotech ecosystem. The company is committed to delivering impactful solutions for patients worldwide.